GWS
EW icon

Greykasell Wealth Strategies’s Edwards Lifesciences EW Stock Holding History

Greykasell Wealth Strategies’s Portfolio EW Stock Details EW Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$19.2K Hold
240
– – 0.01% 334
2025
Q4 		$20.5K Hold
240
– – 0.01% 312
2025
Q3 		$18.7K Hold
240
– – 0.01% 268
2025
Q2 		$18.8K Hold
240
– – 0.01% 226
2025
Q1 		$17.4K Buy
+240
New +$17.2K 0.01% 232

Other funds holding EW

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

Greykasell Wealth Strategies's EW Position: Q1 2026 in Review

Greykasell Wealth Strategies held its Edwards Lifesciences (EW) position steady in Q1 2026 at 240 shares worth $19.2K. The position accounts for 0.01% of the portfolio, ranked #334.

Greykasell Wealth Strategies first reported a position in EW in Q1 2025 and has held it in 5 quarters since. The position peaked at $20.5K in Q4 2025. 1,287 funds tracked by Wall St. Rank hold EW as of Q1 2026.

  • Greykasell Wealth Strategies held 240 shares of Edwards Lifesciences worth $19.2K as of Q1 2026.
  • Greykasell Wealth Strategies left its Edwards Lifesciences share count unchanged in Q1 2026.
  • Edwards Lifesciences made up 0.01% of Greykasell Wealth Strategies's portfolio in Q1 2026, its #334 holding.
  • Greykasell Wealth Strategies first reported a position in Edwards Lifesciences in Q1 2025 and has held it in 5 quarters since.
  • Greykasell Wealth Strategies's Edwards Lifesciences position peaked at $20.5K in Q4 2025.
  • 1,287 funds tracked by Wall St. Rank held Edwards Lifesciences as of Q1 2026.

Based on Greykasell Wealth Strategies's 13F filing for Q1 2026, filed 7 May 2026.